Brought to you by 
NuVasive makes equity investment in Progentix
16 Oct 2017
Executive Summary
NuVasive (minimally invasive devices for spinal surgeries) received exclusive worldwide rights to distribute biomaterials firm Progentix Orthobiology BV's synthetic bone substitutes for ten years. Under certain circumstances, it also has the exclusive option to acquire Progentix.
Deal Industry
- Biotechnology
- Medical Devices
-
Medical Devices
- Biomaterials
- Implantable Devices
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes M&A Option
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NuVasive makes equity investment in Progentix
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice